Liquidia Corp Chairman Sells Shares: Transaction Details & Analysis - News and Statistics
Liquidia Corporation Chairman Stephen M. Bloch recently sold 70,234 shares from his indirect holdings, valued at approximately $2.5 million. This transaction, representing a modest 3.02% of his total reported holdings, is seen as an isolated event for portfolio rebalancing or personal liquidity rather than a change in his long-term outlook on the biotechnology company. Liquidia, focused on pulmonary arterial hypertension, has a market capitalization of $3.32 billion and reported $158.32 million in revenue over the trailing twelve months.
LQDA Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides an overview of Liquidia Corp (LQDA)'s financial performance, detailing its profitability margins such as gross margin (92.33%), operating margin (21.50%), and net margin (15.82%), alongside a negative Return on Equity (-111.05%). It also includes a competitive comparison, highlighting LQDA's gross margin against competitors LEGN (59.70%) and ALMS (100.00%) within its $3.32B market capitalization. The article suggests these metrics offer insight into LQDA's operational efficiency and market position.
Does Wall Street anticipate a 34.47% surge for Liquidia Corporation (LQDA)?
Wall Street analysts project a 34.5% surge for Liquidia Corporation (LQDA), with an average price target of $50.67, driven by a recent 9.2% stock increase and optimistic earnings estimates. While price targets alone aren't definitive, strong analyst consensus and upward revisions in EPS suggest potential for continued growth. Investors are cautioned to consider these insights as part of a broader analysis rather than relying solely on price targets.
Stephen Bloch Sells 62,550 Shares of Liquidia (NASDAQ:LQDA) Stock
Liquidia Director Stephen Bloch sold 62,550 shares of the company's stock for over $2.2 million, reducing his stake by 2.78%. Despite beating earnings expectations with significant revenue growth, Liquidia remains unprofitable with negative margins. The stock currently trades around $37.15, with analysts holding a "Moderate Buy" consensus and an average price target of $43.44.
Wells Fargo Lifts PT on Liquidia Corporation (LQDA) to $51 From $44 – Here’s Why
Wells Fargo increased its price target for Liquidia Corporation (NASDAQ:LQDA) to $51 from $44, reaffirming an Overweight rating due to the anticipated changes in the pulmonary hypertension market and the competitiveness of Liquidia's L606. Oppenheimer also updated its rating, raising the price target to $19 from $16 but reiterating an Underperform rating, crediting the company for a strong early launch of YUTREPIA. The article highlights Liquidia's biopharmaceutical product development and mentions a separate, unrelated promotion for an AI stock with 10,000% upside potential.
Liquidia surges 15% as court clears way for Yutrepia launch
Liquidia stock surged 15% after a district court ruled against United Therapeutics, stating there was no infringement on a key patent related to pulmonary hypertension therapy. This decision allows Liquidia to potentially launch Yutrepia, their treprostinil treatment, which could significantly impact the market.
Liquidia corp director Bloch sells $2.53 million in stock By Investing.com
Liquidia Corp director Stephen M. Bloch sold approximately $2.53 million worth of common stock in multiple transactions on March 26 and March 27, 2026. These sales occurred while Liquidia shares were trading at $35.18, reflecting a 133% gain over the past year. Despite the sales, Bloch retains significant indirect and direct holdings in the company, which analysts expect to turn profitable this year, largely driven by strong revenue from its Yutrepia drug.
Liquidia corp director Bloch sells $2.53 million in stock By Investing.com
Liquidia Corp Director Stephen M. Bloch sold $2.53 million worth of common stock in multiple transactions on March 26 and 27, 2026. The sales occurred while Liquidia shares have seen a 133% gain over the past year and are considered undervalued by analysts, who predict profitability this year. The company recently reported strong Q4 2025 revenue for its Yutrepia drug and analysts have raised price targets.
Venture fund tied to Liquidia (LQDA) trims 70K shares
A venture fund linked to Liquidia director Stephen M. Bloch, Canaan VIII, L.P., sold 70,234 shares of Liquidia common stock across multiple open-market transactions on March 26-27. The sales occurred at weighted average prices between approximately $35 and $37 per share, totaling over $2.5 million. Following these transactions, the fund indirectly holds 2,188,935 shares, while Bloch directly holds 65,712 shares, with Bloch disclaiming beneficial ownership of the fund-held shares beyond his pecuniary interest.
Liquidia corp director Bloch sells $2.53 million in stock
Stephen M. Bloch, a director at Liquidia Corp (NASDAQ:LQDA), recently sold $2.53 million worth of common stock over four transactions on March 26 and 27, 2026, with share prices ranging from $35.4214 to $37.2183. Despite these insider sales, Liquidia's stock has seen a 133% gain over the past year, and analysts anticipate the company will become profitable soon. Bloch still holds over 2.2 million shares indirectly and directly, while the company has reported strong revenue growth for its Yutrepia drug and positive analyst sentiment with raised price targets.
Tudor Investment Corp ET AL Makes New $1.54 Million Investment in Liquidia Corporation $LQDA
Tudor Investment Corp ET AL has made a new investment of $1.54 million in Liquidia Corporation (LQDA), acquiring 67,557 shares in the third quarter. Despite institutional investors owning a significant 64.54% of the stock and analysts issuing "Moderate Buy" ratings with price targets up to $55, company insiders have recently been net sellers. Both the CEO and CFO sold substantial blocks of shares in January, totaling over $8.6 million in insider sales over the last 90 days.
LQDA PE Ratio & Valuation, Is LQDA Overvalued
Liquidia Corp (LQDA) is considered undervalued, with a current forward P/S ratio of 6.83, significantly lower than its five-year average. Its fair price, estimated between $61.06 and $181.57 by the relative valuation method, suggests it is undervalued by 42.25% compared to its current price of $35.26. Despite a high Price-to-Book ratio and negative Free Cash Flow yield, LQDA's P/S ratio is below the industry average, and its robust revenue growth of 3054.65% indicates premium sustainability.
The Chief Commercial Officer of Liquidia (LQDA) Sold 80,000 Shares for $2.8M
Liquidia's Chief Commercial Officer, Scott Moomaw, sold 80,000 shares of LQDA stock for $2.8 million, an exercise and immediate sale executed under a pre-arranged trading plan. Despite the substantial sale, Moomaw retains 188,954 direct shares, valued at approximately $6.8 million, suggesting liquidity management rather than a lack of confidence in the company. Liquidia has shown strong performance with its inhaled pulmonary arterial hypertension drug Yutrepia, leading to an operating profit in Q4 2025.
Canaan VIII LP to sell 62,550 shares of LQDA Common Stock (LQDA)
Canaan VIII LP has filed a Form 144 to disclose a proposed sale of 62,550 shares of Liquidia Corp (LQDA) Common Stock, with UBS Financial Services acting as the broker. The filing also notes a previous sale of 7,684 shares on March 26, 2026. This is considered a routine notice for affiliates before reselling restricted or control securities.
[144] Liquidia Corp SEC Filing
This SEC filing details a Form 144 notice of proposed sale of securities for Liquidia Corp (LQDA). It outlines a proposed sale of 7684 shares of common stock by an unnamed filer, acquired through a pre-IPO investment in 2018. The filing indicates a neutral sentiment and impact, with the proposed sale set to occur on March 26, 2026, through UBS Financial Services Inc.
BofA Securities Raises Liquidia Corporation (LQDA) PT to $37, Reiterates Buy Rating
BofA Securities has increased its price target for Liquidia Corporation (LQDA) to $37, while maintaining a Buy rating on the stock. This adjustment reflects the firm's positive outlook on the company's future performance and potential.
Why Liquidia Corporation Shares Are Surging Higher
Liquidia Corporation (LQDA) shares are rising due to a bullish stance from Wells Fargo, which highlighted the company's strong commercial momentum and rapid adoption of its pulmonary hypertension drug, YUTREPIA. This follows Liquidia beating earnings expectations on March 5 and Wells Fargo subsequently raising its price target to $51 on March 23, 2026. The surge is attributed to company-specific factors indicating growing confidence in Liquidia's revenue and execution.
Liquidia Corp CCO Moomaw sells $673k in shares
Liquidia Corp's Chief Commercial Officer, Scott Moomaw, sold 18,314 shares of common stock for a total of $673,751 on March 23, 2026, under a pre-arranged trading plan. Concurrently, Moomaw exercised options to acquire 17,000 shares. The company has seen a 126% return over the past year, with analysts expecting profitability and a positive outlook for its Yutrepia drug.
Liquidia Corp CCO Moomaw sells $673k in shares
Liquidia Corp's Chief Commercial Officer, Scott Moomaw, sold 18,314 shares of company stock for $673,751 and exercised options to acquire 17,000 shares for $57,800. These transactions were executed under a pre-arranged 10b5-1 trading plan. The company's stock has seen a 126% return over the past year, and analysts predict profitability this year, with strong revenue growth and positive price target revisions from several firms.
Scott Moomaw Sells 18,314 Shares of Liquidia (NASDAQ:LQDA) Stock
Scott Moomaw, Chief Commercial Officer of Liquidia (NASDAQ:LQDA), recently sold 18,314 shares of the company's stock for approximately $673,772, reducing his position by 8.89%. This transaction follows a previous sale in January and comes after Liquidia reported strong Q4 results, beating EPS and revenue estimates, which led to a roughly 4% increase in stock price. Analysts maintain a "Moderate Buy" consensus with a $43.44 target, and institutional ownership remains high at about 64.5%.
[Form 4] Liquidia Corp Insider Trading Activity
Liquidia Corp Chief Commercial Officer Scott Moomaw exercised stock options and subsequently sold shares through a planned transaction under a Rule 10b5-1 trading plan. He acquired 17,000 shares at $3.40 each and sold 17,000 shares at a volume-weighted average price of $36.8128, plus an additional 1,314 shares at $36.48. Following these transactions, Moomaw directly holds 187,640 shares.
Liquidia Corp (LQDA) Trading 4.64% Higher on Mar 25
Liquidia Corp (LQDA) saw its shares surge 4.64% in mid-day trading on March 25, settling at $36.84. This places the stock significantly above its 52-week low, and analysts forecast an average target price of $49.89, indicating a potential upside of 35.42%. GuruFocus estimates suggest an even higher potential upside of 920.87% based on its GF Value of $376.09.
Liquidia Stock Up 135% as Insider Sells $1.3 Million in Shares
Liquidia's Chief Medical Officer, Rajeev Saggar, sold 35,365 shares worth $1.28 million, a sale significantly larger than his previous transactions. This insider sale comes as Liquidia's stock has surged 135% in the last year, driven by strong product sales and profitability from its YUTREPIA launch. Despite a net loss for the full year due to scaling efforts, the company maintains a strong cash position, and the transaction is viewed as an insider locking in gains rather than a sign of weakness.
LQDA: Wells Fargo Raises Price Target to $51, Maintains Overweig
Wells Fargo analyst Benjamin Burnett raised the price target for Liquidia (LQDA) to $51 from $44, maintaining an "Overweight" rating. This increase reflects continued analyst confidence, with other firms also recently raising their price targets. Liquidia, a biopharmaceutical company focused on pulmonary hypertension treatments, has an average analyst target price of $49.89, suggesting a significant upside.
Can Liquidia Corporation (LQDA) run higher on rising earnings estimates?
This article analyzes whether Liquidia Corporation (LQDA) stock is likely to increase due to rising earnings estimates. It suggests that upward revisions in earnings forecasts are a primary driver of short-term stock price momentum. Investors are advised to consider the magnitude and direction of these revisions to predict future stock movements.
Wall Street analysts see a 35.35% upside in Liquidia Corporation (LQDA): Can the stock really move this high?
This article discusses the 35.35% upside potential that Wall Street analysts see in Liquidia Corporation (LQDA). It questions whether the stock can genuinely reach this high target. The content, though empty in the provided input, would typically delve into the reasons behind this optimistic forecast.
Wall Street analysts see a 35.35% upside in Liquidia Corporation (LQDA): Can the stock really move this high?
This article discusses the 35.35% upside potential that Wall Street analysts see in Liquidia Corporation (LQDA). It suggests analyzing key factors like ratings, price targets, and underlying business fundamentals to determine if the stock can indeed reach this high. The piece implies that this analysis will help investors make informed decisions about LQDA's future performance.
Insight Wealth Strategies LLC Purchases New Position in Liquidia Corporation $LQDA
Insight Wealth Strategies LLC has acquired a new position in Liquidia Corporation (NASDAQ:LQDA), purchasing 141,818 shares valued at approximately $4.89 million. This investment highlights broader institutional interest in Liquidia, with other major investors also increasing their stakes. Despite recent analyst upgrades and strong quarterly revenue growth, the company remains unprofitable with negative margins.
Liquidia Corporation $LQDA Shares Sold by Mirabella Financial Services LLP
Mirabella Financial Services LLP significantly reduced its stake in Liquidia Corporation by 45.2% in the third quarter, now holding 0.28% of the company. Despite insider selling totaling $7.96 million last quarter, Liquidia exceeded quarterly earnings and revenue estimates. Analysts currently rate Liquidia a "Moderate Buy" with an average price target of $42.67.
Liquidia (LQDA) Is Down 5.1% After Q4 Profitability And New Shelf Filings - What's Changed
Liquidia (LQDA) recently announced its Q4 2025 earnings, reporting a shift to profitability with US$92.02 million in revenue and US$14.56 million in net income. Concurrently, the company filed multiple shelf registrations for various securities, signaling potential future capital needs for expansion and pipeline development. While quarterly profitability is encouraging, the long-term investment narrative still depends on sustained performance of YUTREPIA and managing legal and payer-related risks.
Liquidia Retail Buzz Surges After BofA Raises Price Target to $25 On Yutrepia FDA Nod
Liquidia Corporation (LQDA) is experiencing a surge in retail investor interest following Bank of America's raised price target of $25 on the heels of the FDA's approval of Yutrepia. The Yutrepia approval, aimed at treating pulmonary arterial hypertension, is expected to significantly boost the company's financial outlook, with analysts forecasting peak sales around $1.5 billion. This positive development has led to increased stock activity and a bullish outlook from analysts.
Liquidia Corporation (LQDA) gains momentum following overturning of district court patent ruling
Liquidia Corporation (LQDA) has seen its stock gain momentum after a district court ruling regarding a patent was overturned. This positive development likely impacts the company's intellectual property position and future prospects. Investors are reacting favorably to the news.
Wall Street experts predict Liquidia Corporation (LQDA) could climb by 35.35%. Is it possible for the stock to reach this level?
Wall Street analysts project that Liquidia Corporation (LQDA) could see a 35.4% increase, with an average price target of $49.89. Despite the consensus, the article cautions investors that analyst price targets can be overly optimistic and advises considering other factors. Liquidia's strong Zacks Rank #1 (Strong Buy) and recent upward revisions in EPS estimates suggest potential for near-term gains, even if the exact target is not met.
Liquidia (NASDAQ:LQDA) Announces Quarterly Earnings Results, Beats Estimates By $0.14 EPS
Liquidia (NASDAQ:LQDA) announced quarterly earnings, reporting an EPS of $0.15, significantly beating the consensus estimate of $0.01. Despite a substantial 3072.4% year-over-year revenue increase, the company remains unprofitable with a negative net margin and return on equity. Analysts maintain a "Moderate Buy" rating with a consensus price target of $42.67, following recent price target upgrades and mixed insider selling activity.
Liquidia (LQDA) Is Down 5.1% After Q4 Profitability And New Shelf Filings - What's Changed
Liquidia Corporation reported a significant shift to profitability in Q4 2025, with revenues reaching US$92.02 million and net income of US$14.56 million, alongside the filing of new shelf registrations for potential future capital needs. Despite positive Q4 results and a strong revenue forecast for 2029, the stock experienced a 5.1% drop, with analysts holding cautious views due to litigation risks and uncertainty around YUTREPIA's market sustainability. The article emphasizes the importance of understanding the company's investment narrative, including the impact of payer terms and competitive data on earnings, and advises investors to form their own convictions based on comprehensive data analysis.
Recent Insider Transactions at Liquidia Corp
Several high-level executives at Liquidia Corp (LQDA) recently sold significant amounts of company stock. Director Raman Singh sold shares totaling over $720,000, Chief Human Resource Officer Sarah Krepp sold shares worth over $617,000, and Chief Medical Officer Rajeev Saggar sold shares exceeding $1.2 million, all on March 13, 2026. After these transactions, each executive retains a substantial number of shares, including unvested restricted stock units.
Liquidia (LQDA) CMO trims stake with 35,365-share open-market sale
Liquidia Corp's Chief Medical Officer, Rajeev Saggar, sold 35,365 shares of common stock in an open-market transaction on March 13, 2026, at a volume-weighted average price of $36.3024. Following this sale, Saggar still directly holds 174,473 shares, including unvested restricted stock units from various grants and shares from an employee stock purchase plan. The sale is categorized as a discretionary transaction, but his remaining substantial equity position suggests it's for diversification or liquidity rather than a complete exit.
Liquidia (LQDA) director sells 20,000 shares after exercising options
Liquidia Corp director Raman Singh exercised options for 20,000 shares at $4.86 per share and subsequently sold these 20,000 shares at a volume-weighted average price of $36.0414. After these transactions, Singh directly holds 38,755 common shares and 18,396 unvested restricted stock units. The Form 4 filing also corrected an administrative error from a previous filing regarding an omitted options exercise.
Liquidia (LQDA) HR chief sells 16,261 shares, keeps 148,397
Liquidia Corp's Chief Human Resource Officer, Sarah Krepp, reported an open-market sale of 16,261 shares of common stock at $38.00 per share. Following this transaction, Krepp directly holds 148,397 common shares, in addition to various unvested RSU awards and shares acquired through the company’s employee stock purchase plan. The sale was documented in an SEC Form 4 filing and has been categorized with a "Very High" impact and "Negative" sentiment.
Mirabella Financial Services LLP Trims Stake in Liquidia Corporation $LQDA
Mirabella Financial Services LLP significantly reduced its stake in Liquidia Corporation by 45.2% during the third quarter of 2025, selling over 200,000 shares. Despite this, Liquidia reported strong financial results, beating quarterly estimates with a revenue increase of over 3000% year-over-year. Analysts currently hold a "Moderate Buy" consensus rating for Liquidia with an average target price of $42.67.
Zacks Industry Outlook Features Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals, and Liquidia
Zacks Equity Research has highlighted Terns Pharmaceuticals (TERN), ADMA Biologics (ADMA), ANI Pharmaceuticals (ANIP), and Liquidia Corp. (LQDA) as top biotech stocks poised for outperformance based on strong Q4 earnings, regulatory approvals, and M&A activity. The biotechnology sector continues to show resilience despite economic challenges, driven by innovation, strategic partnerships, and AI integration in drug discovery. The report delves into key trends, industry rankings, valuation, and provides details on why each of the four featured companies is well-positioned for growth.
Zacks Industry Outlook Highlights Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals and Liquidia
The biotech industry has shown strong performance in 2026 driven by innovation, M&A activity, and new drug approvals, despite an uncertain macroeconomic climate. This Zacks Industry Outlook highlights four companies—Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals, and Liquidia Corp.—that are positioned for potential outperformance due to strong product pipelines and market traction. The report also details major trends like AI in drug discovery and precision medicine, which are shaping the industry's future.
HighVista Strategies LLC Acquires 55,844 Shares of Liquidia Corporation $LQDA
HighVista Strategies LLC increased its stake in Liquidia Corporation by 46.3% during the third quarter, purchasing an additional 55,844 shares to hold a total of 176,485 shares valued at approximately $4.01 million. This makes Liquidia the firm's 28th-largest position. The article also notes recent insider selling by Liquidia's CEO and CFO, and provides an overview of analyst ratings, with a consensus "Moderate Buy" and an average price target of $42.67.
Farallon Capital Management LLC Purchases 4,326,876 Shares of Liquidia Corporation $LQDA
Farallon Capital Management LLC significantly increased its stake in Liquidia Corporation (NASDAQ:LQDA) by 102.1% in the third quarter, acquiring an additional 4,326,876 shares. This purchase brings their total holdings to 8,565,638 shares, valued at $194,783,000, representing approximately 9.85% of the company. Other institutional investors like Vanguard Group Inc. and Opaleye Management Inc. also boosted their positions in LQDA, and analysts generally have a "Moderate Buy" rating for the stock.
Divisadero Street Capital Management LP Invests $3.59 Million in Liquidia Corporation $LQDA
Divisadero Street Capital Management LP has bought 158,004 shares of Liquidia Corporation (NASDAQ:LQDA), a new position valued at $3.59 million, representing approximately 0.18% of the company. Despite insider selling activity, institutional investors like Goldman Sachs and Geode Capital Management have also increased their stakes. Analysts maintain a "Moderate Buy" rating for Liquidia, with a target price of $42.67, following the company's recent beat on quarterly earnings and revenue estimates.
Assessing Liquidia (LQDA) Valuation After Strong Earnings And YUTREPIA Driven Momentum
Liquidia (LQDA) has shown strong momentum after its recent earnings report, with increased revenue and a swing to net income driven by sales of its lead therapy, YUTREPIA. While analysts project significant future growth and a fair value of $44.00, suggesting undervaluation, the company's high P/S ratio of 21.5x warrants caution. Investors are advised to consider both the optimistic growth forecasts and potential risks, such as payer coverage for YUTREPIA.
Liquidia (NASDAQ: LQDA) CCO sells 80K shares after option exercise
Liquidia Corp's Chief Commercial Officer, Moomaw Scott, exercised stock options for 80,000 shares and subsequently sold all 80,000 shares at a volume-weighted average price of $35.3228. This transaction was part of a pre-arranged Rule 10b5-1 trading plan established on November 7, 2025. Following these transactions, Moomaw Scott directly owns 188,954 shares of Liquidia common stock, along with unvested restricted stock units.
Liquidia Corp (LQDA) Stock Price Up 4.74% on Mar 10
Liquidia Corp (LQDA) saw its stock price increase by 4.74% on March 10, trading at $37.56 by mid-day, after reaching a high of $37.95. This places LQDA 19.52% below its 52-week high and 233.57% above its 52-week low. Analyst forecasts suggest an average target price of $49.44, implying a 31.64% upside, with a consensus "Outperform" rating, while GuruFocus estimates a one-year GF Value of $337.90, indicating a significant 799.63% upside.
Best Momentum Stocks to Buy for March 10th
This article identifies three top momentum stocks for March 10th: Sterling Infrastructure (STRL), Liquidia Corporation (LQDA), and NWPX Infrastructure (NWPX). All three companies hold a Zacks Rank #1 and have seen positive revisions to their current year earnings estimates. The article also highlights their strong stock performance relative to the S&P 500 over the past three months and their strong Momentum Scores.
Planned 97,000-share option exercise and insider sales reported (LQDA)
A Form 144 filing by Morgan Stanley Smith Barney LLC for Liquidia Corp (LQDA) reports planned transfers of common stock totaling 97,000 shares from an option exercise on March 9, 2026, alongside other employee stock plan transfers. The filing also details recent open-market dispositions by Scott Moomaw, including sales of 827 shares on March 2, 2026, for $25,289.66 and 20,533 shares on January 12, 2026, for $768,550.19. This is described as a routine Rule 144 disclosure with a neutral impact and sentiment.
